Bio

Andrea’s responsibilities include research and investment analysis, deal execution, portfolio analytics, financing and investor relations. She is a member of the Investment Committee and the chair of the Valuation Committee. Since joining DRI Capital in 2003, Andrea has led the evaluation of more than 200 pharmaceutical products in 16 of the global top 20 therapeutic classes, developing substantial expertise in the scientific, clinical, regulatory and commercial aspects of the pharmaceutical industries operating in the United States, Europe and Japan. Andrea has conducted diligence that led to the acquisition of more than 40 different royalty assets. Since 2010, Andrea has played a leading role in the debt issuances for DRI’s managed funds. She has also played an active role in raising more than $2.3 billion in equity commitments for DRI’s managed funds. Prior to joining DRI Capital, Andrea worked at Sanofi Pasteur, the vaccines division of Sanofi, where she contributed to global licensing applications and regulatory filings. In addition, she was instrumental in the launch of a new vaccine manufacturing facility. Andrea began her career at Allelix Biopharmaceuticals Inc. (now NPS Pharmaceuticals Inc.) where she conducted clinical analysis which contributed to the development of purification processes for two biologic products. Andrea received a B.Sc. in Biochemistry with a specialization in Biotechnology from the University of Waterloo and an MBA from Queen's University. She is a member of the Women Business Leaders of the US Healthcare Industry Foundation.